Diakonos’ brain tumour vaccine wins FDA’s orphan drug designation
The immuno-oncology company has also completed enrolment in a Phase I trial investigating its dendritic cell vaccine DOC1021.
The immuno-oncology company has also completed enrolment in a Phase I trial investigating its dendritic cell vaccine DOC1021.
What's Your Reaction?
